134 related articles for article (PubMed ID: 22781792)
1. [Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation].
Miao M; Wu DP; Cao XS; Dong WM; Wang B; Ou YJ; Li ZY; Li DP; Yang MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):362-5. PubMed ID: 22781792
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial.
Han TT; Xu LP; Liu DH; Liu KY; Wang FR; Wang Y; Yan CH; Chen YH; Sun YQ; Ji Y; Wang JZ; Zhang XH; Huang XJ
Ann Hematol; 2015 Jan; 94(1):117-28. PubMed ID: 25069650
[TBL] [Abstract][Full Text] [Related]
3. [Hematopoietic reconstitution on the prognosis of hematological malignancies after allogeneic hematopoietic stem cell transplantation].
Zhang Y; Ren HY; Qiu ZX; Wang MJ; Xu WL; Liu W; Li Y; Dong YJ; Yin Y; Sun YH; Wang LH; Ou JP; Wang WS; Cen XN
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):747-50. PubMed ID: 23336230
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.
Fu A; Peng Y; Cheng P; Wu J; Zhu X; Yang Y; Huang L; Wang N; Wang J; Xu J; Wan Y; Cao Y; Wei J; Xiao Y; Meng F; Cheng H; Zhang Y; Zhang D
Transplant Cell Ther; 2024 May; 30(5):500-509. PubMed ID: 38447750
[TBL] [Abstract][Full Text] [Related]
5. Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution.
Fu H; Zhang X; Xu L; Liu K; Huang X
Clin Transplant; 2016 Feb; 30(2):170-8. PubMed ID: 26589669
[TBL] [Abstract][Full Text] [Related]
6. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant.
Maharaj D; Steinberg JP; Gouvea JV; Gieser PW
Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183
[TBL] [Abstract][Full Text] [Related]
7. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study.
Liu K; Chen Y; Zeng Y; Xu L; Liu D; Chen H; Zhang X; Han W; Wang Y; Zhao T; Wang J; Wang J; Han Q; Zhao C; Huang X
Stem Cells Dev; 2011 Oct; 20(10):1679-85. PubMed ID: 21142788
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.
Li Y; Kong F; Bai G; Jiang Y; Zhang W; Sun X; Sui X; Li Y; Ding M; Yuan D; Wang X; Fang X
Front Immunol; 2024; 15():1340908. PubMed ID: 38650933
[TBL] [Abstract][Full Text] [Related]
9. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
[TBL] [Abstract][Full Text] [Related]
10. [Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation].
Jiang Q; Huang XJ; Liu KY; Chen H; Chen YH; Gao ZY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):173-7. PubMed ID: 16792919
[TBL] [Abstract][Full Text] [Related]
11. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.
Wen B; Zhang X; Chen S; Fan J; Yang S; Cai Y; Wang P; Zhang Q; Gu Q; Du X
Hematol Oncol; 2022 Oct; 40(4):777-786. PubMed ID: 35554955
[TBL] [Abstract][Full Text] [Related]
12. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
13. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
Sawada H; Wake A; Yamasaki Y; Izumi Y
Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
[TBL] [Abstract][Full Text] [Related]
14. [Effects of recombinant human interleukin 11 on hematological malignancy after allogeneic hematopoietic cell transplantation].
Xu XJ; Niu XM; Guo ZW; He HQ; Qiu DF; Liu C; Lin SH; Song K; Ren ZJ; Li WC; Huang GN; Liu QF
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(2):100-2. PubMed ID: 21418991
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
16. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.
Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
Transfusion; 2005 Jul; 45(7):1064-72. PubMed ID: 15987349
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
[TBL] [Abstract][Full Text] [Related]
20. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
